Ani Pharmaceuticals (ANIP) Profit After Tax (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Profit After Tax data on file, last reported at $29.5 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 88.07% year-over-year to $29.5 million; the trailing twelve-month figure through Mar 2026 stood at $92.1 million (up 537.8% YoY), and the FY2025 full-year result was $78.3 million, up 522.94% from the prior year.
• Profit After Tax climbed to $29.5 million in Q1 2026, from $27.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $29.5 million in Q1 2026 to a low of -$24.2 million in Q3 2024.
• A 5-year average of $3.5 million and a median of $1.4 million in 2023 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax sank 23977.91% in 2022 and soared 1165.25% in 2024, its largest moves.
• Tracing ANIP's Profit After Tax over 5 years: stood at -$4.2 million in 2022, then soared by 127.22% to $1.2 million in 2023, then tumbled by 989.7% to -$10.3 million in 2024, then jumped by 367.52% to $27.5 million in 2025, then climbed by 7.28% to $29.5 million in 2026.
• Business Quant data shows ANIP's Profit After Tax at $29.5 million in Q1 2026, $27.5 million in Q4 2025, and $26.6 million in Q3 2025.